CoChat
Sign Up
Cited by 471

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9

Li, Hongmei Lisa, Fujimoto, Naoko, Sasakawa, Noriko, Shirai, Saya, Ohkame, Tokiko, Sakuma, Tetsushi, Tanaka, Michihiro, Amano, Naoki, Watanabe, Akira, Sakurai, Hidetoshi, Yamamoto, Takashi, Yamanaka, Shinya, Hotta, Akitsu·2015·Stem Cell Reports
DOI 10.1016/j.stemcr.2014.10.013PMC PMC4297888
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.stemcr.2014.10.013

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 11 references

Research works printed but not linked: 38

  1. Aartsma-Rus, 2009, Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations, Hum. Mutat., 30, 293, 10.1002/humu.20918 · DOI
  2. Amps, 2011, Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage, Nat. Biotechnol., 29, 1132, 10.1038/nbt.2051 · DOI
  3. Bae, 2014, Microhomology-based choice of Cas9 nuclease target sites, Nat. Methods, 11, 705, 10.1038/nmeth.3015 · DOI
  4. Bae, 2014, Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases, Bioinformatics, 30, 1473, 10.1093/bioinformatics/btu048 · DOI · Paper page
  5. Canver, 2014, Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells, J. Biol. Chem., 289, 21312, 10.1074/jbc.M114.564625 · DOI
  6. Choi, 2013, Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells, Hepatology, 57, 2458, 10.1002/hep.26237 · DOI
  7. Ding, 2013, A TALEN genome-editing system for generating human stem cell-based disease models, Cell Stem Cell, 12, 238, 10.1016/j.stem.2012.11.011 · DOI
  8. Ding, 2013, Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs, Cell Stem Cell, 12, 393, 10.1016/j.stem.2013.03.006 · DOI · Paper page
  9. Filareto, 2013, An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells, Nat. Commun., 4, 1549, 10.1038/ncomms2550 · DOI
  10. Goudenege, 2012, Myoblasts derived from normal hESCs and dystrophic hiPSCs efficiently fuse with existing muscle fibers following transplantation, Mol. Ther., 20, 2153, 10.1038/mt.2012.188 · DOI
  11. Heigwer, 2014, E-CRISP: fast CRISPR target site identification, Nat. Methods, 11, 122, 10.1038/nmeth.2812 · DOI
  12. Hockemeyer, 2011, Genetic engineering of human pluripotent cells using TALE nucleases, Nat. Biotechnol., 29, 731, 10.1038/nbt.1927 · DOI
  13. Hotta, 2009, Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency, Nat. Methods, 6, 370, 10.1038/nmeth.1325 · DOI
  14. Koehler, 2011, The uniqueome: a mappability resource for short-tag sequencing, Bioinformatics, 27, 272, 10.1093/bioinformatics/btq640 · DOI
  15. Langmead, 2009, Searching for SNPs with cloud computing, Genome Biol., 10, R134, 10.1186/gb-2009-10-11-r134 · DOI
  16. Li, 2014, Genetic correction using engineered nucleases for gene therapy applications, Dev. Growth Differ., 56, 63, 10.1111/dgd.12107 · DOI
  17. Ma, 2013, Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free β-thalassemia induced pluripotent stem cells, J. Biol. Chem., 288, 34671, 10.1074/jbc.M113.496174 · DOI
  18. Maetzel, 2014, Genetic and chemical correction of cholesterol accumulation and impaired autophagy in hepatic and neural cells derived from Niemann-Pick Type C patient-specific iPS cells, Stem Cell Rep., 2, 866, 10.1016/j.stemcr.2014.03.014 · DOI · Paper page
  19. Matsui, 2014, Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A, PLoS ONE, 9, e104957, 10.1371/journal.pone.0104957 · DOI
  20. Okada, 2013, Current challenges and future directions in recombinant AAV-mediated gene therapy of Duchenne muscular dystrophy, Pharmaceuticals (Basel), 6, 813, 10.3390/ph6070813 · DOI
  21. Okita, 2011, A more efficient method to generate integration-free human iPS cells, Nat. Methods, 8, 409, 10.1038/nmeth.1591 · DOI · Paper page
  22. Osborn, 2013, TALEN-based gene correction for epidermolysis bullosa, Mol. Ther., 21, 1151, 10.1038/mt.2013.56 · DOI · Paper page
  23. Ousterout, 2013, Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients, Mol. Ther., 21, 1718, 10.1038/mt.2013.111 · DOI
  24. Pichavant, 2011, Current status of pharmaceutical and genetic therapeutic approaches to treat DMD, Mol. Ther., 19, 830, 10.1038/mt.2011.59 · DOI
  25. Popplewell, 2013, Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in, Hum. Gene Ther., 24, 692, 10.1089/hum.2013.081 · DOI
  26. Rousseau, 2011, Endonucleases: tools to correct the dystrophin gene, J. Gene Med., 13, 522, 10.1002/jgm.1611 · DOI
  27. Sakuma, 2013, Efficient TALEN construction and evaluation methods for human cell and animal applications, Genes Cells, 18, 315, 10.1111/gtc.12037 · DOI
  28. Sakuma, 2013, Repeating pattern of non-RVD variations in DNA-binding modules enhances TALEN activity, Sci. Rep., 3, 3379, 10.1038/srep03379 · DOI
  29. Sebastiano, 2011, In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases, Stem Cells, 29, 1717, 10.1002/stem.718 · DOI
  30. Soldner, 2011, Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations, Cell, 146, 318, 10.1016/j.cell.2011.06.019 · DOI · Paper page
  31. Sugiura, 2014, Induced pluripotent stem cell generation-associated point mutations arise during the initial stages of the conversion of these cells, Stem Cell Rep., 2, 52, 10.1016/j.stemcr.2013.11.006 · DOI
  32. Suzuki, 2014, Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones, Cell Stem Cell, 15, 31, 10.1016/j.stem.2014.06.016 · DOI · Paper page
  33. Takahashi, 2007, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131, 861, 10.1016/j.cell.2007.11.019 · DOI · Paper page
  34. Tanaka, 2013, Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi Myopathy in vitro, PLoS ONE, 8, e61540, 10.1371/journal.pone.0061540 · DOI
  35. Tuffery-Giraud, 2009, Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase, Hum. Mutat., 30, 934, 10.1002/humu.20976 · DOI
  36. Ye, 2014, Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection, Proc. Natl. Acad. Sci. USA, 111, 9591, 10.1073/pnas.1407473111 · DOI · Paper page
  37. Zou, 2011, Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease, Blood, 118, 4599, 10.1182/blood-2011-02-335554 · DOI
  38. Zou, 2011, Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting, Blood, 117, 5561, 10.1182/blood-2010-12-328161 · DOI

Cited by

Sorted by citations

See all 471

Metadata

Authors
Li, H. L., Fujimoto, N., Sasakawa, N., Shirai, S., Ohkame, T., Sakuma, T., Tanaka, M., Amano, N., Watanabe, A., Sakurai, H., Yamamoto, T., Yamanaka, S., & Hotta, A.
Venue
Stem Cell Reports
Publisher
Elsevier BV
Published
2015-01
Volume
4
Issue
1
Pages
143-154
ISSN
2213-6711
DOI
10.1016/j.stemcr.2014.10.013
PMC
PMC4297888
Cited by
471
References
11
Language
en
Licence
Funders
  • JSPS KAKENHI
  • JST PRESTO
  • JST Yamanaka iPS Cell Special Project
  • JST Research Center Network for Realization of Regenerative Medicine
  • JSPS

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review